Clinical Trials of Intravenous Immunoglobulin for Alzheimer's Disease

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2014 Apr 25

PMID 24760112

Citations 30

Authors

Norman Relkin

Affiliations

Soon will be listed here.

Abstract

The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002. Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders. In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism. Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD. However, positive cognitive signals were observed in pre-planned subgroup analyses among APOE-ε4 carriers and moderately impaired AD patients. Biomarker studies revealed dose dependent increases in plasma and CSF immunoglobulins and decreases in beta amyloid-42 levels. In addition, IVIG treatment was generally safe and well-tolerated. These findings suggest that naturally occurring human anti-amyloid antibodies may play a physiologic role in the clearance of aggregated amyloid proteins. While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG's mechanisms are warranted and may guide the development of more effective therapies for AD in the future.

Citing Articles

Intruders or protectors - the multifaceted role of B cells in CNS disorders.

Aspden J, Murphy M, Kashlan R, Xiong Y, Poznansky M, Sirbulescu R Front Cell Neurosci. 2024; 17:1329823.

PMID: 38269112 PMC: 10806081. DOI: 10.3389/fncel.2023.1329823.

Serum immunoglobulins and biomarkers of dementia: a population-based study.

Yaqub A, Khan S, Vernooij M, van Hagen P, Peeters R, Ikram M Alzheimers Res Ther. 2023; 15(1):194.

PMID: 37936180 PMC: 10629143. DOI: 10.1186/s13195-023-01333-3.

Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.

Alshamrani M Antibodies (Basel). 2023; 12(2).

PMID: 37366656 PMC: 10295010. DOI: 10.3390/antib12020041.

The Immune System as a Therapeutic Target for Alzheimer's Disease.

Zieneldien T, Kim J, Sawmiller D, Cao C Life (Basel). 2022; 12(9).

PMID: 36143476 PMC: 9506058. DOI: 10.3390/life12091440.

Immune Response at the Crossroads of Atherosclerosis and Alzheimer's Disease.

Stahr N, Galkina E Front Cardiovasc Med. 2022; 9:870144.

PMID: 35872901 PMC: 9298512. DOI: 10.3389/fcvm.2022.870144.

References

Kaveri S . Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012; 11(11):792-4. DOI: 10.1016/j.autrev.2012.02.006. View

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

Ferreira S, Klein W . The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011; 96(4):529-43. PMC: 4390395. DOI: 10.1016/j.nlm.2011.08.003. View

Enciu A, Popescu B . Is there a causal link between inflammation and dementia?. Biomed Res Int. 2013; 2013:316495. PMC: 3690213. DOI: 10.1155/2013/316495. View

Fillit H, Hess G, Hill J, Bonnet P, Toso C . IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009; 73(3):180-5. DOI: 10.1212/WNL.0b013e3181ae7aaf. View

Schultz S, Khosrowshahi L, Agnew A, Olali E, Devi G . A retrospective chart review of the tolerability and efficacy of intravenous immunoglobulin in the treatment of Alzheimer's disease. J Am Geriatr Soc. 2008; 56(4):772-4. DOI: 10.1111/j.1532-5415.2008.01620.x. View

Gaskin F, Finley J, Fang Q, Xu S, Fu S . Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J Exp Med. 1993; 177(4):1181-6. PMC: 2190957. DOI: 10.1084/jem.177.4.1181. View

ONuallain B, Williams A, McWilliams-Koeppen H, Acero L, Weber A, Ehrlich H . Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol. 2010; 30 Suppl 1:S37-42. PMC: 2883095. DOI: 10.1007/s10875-010-9413-6. View

Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. DOI: 10.1056/NEJMoa1312889. View

10.

Weksler M, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P . Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002; 37(7):943-8. DOI: 10.1016/s0531-5565(02)00029-3. View

11.

Salloway S, Sperling R, Fox N, Blennow K, Klunk W, Raskind M . Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):322-33. PMC: 4159618. DOI: 10.1056/NEJMoa1304839. View

12.

Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S . Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol. 2002; 52(2):253-6. DOI: 10.1002/ana.10253. View

13.

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S . Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013; 12(3):233-43. PMC: 4986921. DOI: 10.1016/S1474-4422(13)70014-0. View

14.

Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H . Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation. 2012; 9:105. PMC: 3416679. DOI: 10.1186/1742-2094-9-105. View

15.

Szabo P, Mujalli D, Rotondi M, Sharma R, Weber A, Schwarz H . Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol. 2010; 227(1-2):167-74. DOI: 10.1016/j.jneuroim.2010.06.010. View

16.

Dodel R, Du Y, Depboylu C, Hampel H, Frolich L, Haag A . Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004; 75(10):1472-4. PMC: 1738770. DOI: 10.1136/jnnp.2003.033399. View

17.

Relkin N, Szabo P, Adamiak B, Burgut T, Monthe C, Lent R . 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008; 30(11):1728-36. DOI: 10.1016/j.neurobiolaging.2007.12.021. View

18.

Rinne J, Brooks D, Rossor M, Fox N, Bullock R, Klunk W . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9(4):363-72. DOI: 10.1016/S1474-4422(10)70043-0. View

19.

Hardy J, Allsop D . Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12(10):383-8. DOI: 10.1016/0165-6147(91)90609-v. View

20.

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B . Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001; 57(5):801-5. DOI: 10.1212/wnl.57.5.801. View